A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Inclusion Criteria

• •Have acute T-cell lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
• •T-ALL or T-LBL participants with relapsed/refractory disease.
• •Have had at least 60 days between prior hematopoietic stem cell transplantation (SCT) and first dose of study drug.
• •Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale for adults.
• •Lansky score \>50% for participants \<16 years old.
• •Have adequate organ function.
• •Are at least:
• •* adult Phase 1 Part A and Phase 2: ≥16 years old at the time of screening
• •* pediatric Phase 1 Part B: 2 to \<16 years old
• •Men and women with reproductive potential: Must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug(s) or country requirements, whichever is longer.
• •Females with childbearing potential: Have had a negative serum pregnancy test ≤7 days before the first dose of study drug and also must not be breastfeeding.
• •Are able to swallow capsules and tablets.